FDA of­fi­cials raise con­cerns with im­munother­a­py overuse for ear­ly-stage can­cer pa­tients: #AACR24

SAN DIEGO — As im­munother­a­pies be­come more wide­ly used be­fore and af­ter can­cer surgery, the FDA is wor­ried that some pa­tients may be re­ceiv­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.